HCRN Research Archives - Page 2 of 2 - Hoosier Cancer Research Network

ADAPT-BLADDER study compares novel immunotherapy combinations and BCG re-treatment in non-muscle invasive bladder cancer

Hoosier Cancer Research Network (HCRN) has opened a study for patients with non-muscle invasive bladder cancer who were previously treated with the Bacillus Calmette-Guerin (BCG) vaccine. The randomized phase I/II clinical trial will test standard re-treatment with BCG against the immunotherapeutic agent durvalumab combined with BCG, or durvalumab combined with radiation therapy.

Hoimes presents GU14-188 study at ESMO

Christopher J. Hoimes, DO, presented the Hoosier Cancer Research Network study GU14-188 at a poster discussion session October 20 during the 2018 European Society of Medical Oncology (ESMO) Congress in Munich, Germany. Dr. Hoimes is sponsor-investigator of the study of neoadjuvant pembrolizumab and chemotherapy for locally advanced urothelial cancer. See the HCRN GU14-188 poster and […]

HCRN study explores investigational vaccine therapy for metastatic colorectal cancer

Rutgers Cancer Institute of New Jersey is offering a Hoosier Cancer Research Network clinical trial (HCRN GI16-288) targeting an advanced form of colorectal cancer with a combination vaccine/immunotherapy treatment. The standard way of treating colorectal cancer that has spread to the liver or has recurred is with a combination of chemotherapy and removal of the […]

New study compares chemotherapy options with nivolumab in cisplatin-ineligible metastatic bladder cancer

A new Hoosier Cancer Research Network study may help researchers determine whether the choice of chemotherapy regimens used in combination with the immunotherapy drug nivolumab could make a difference in outcomes for patients with metastatic bladder cancer. Standard treatment for metastatic bladder cancer, also known as urothelial carcinoma, usually involves cisplatin-based chemotherapy. However, a large […]

Junior IU oncologist presents oral abstract at world’s leading oncology group

Story provided courtesy of IU Simon Cancer Center. Less than two years ago, Greg Durm, MD, was finishing up his hematology-oncology fellowship at IU School of Medicine. Now he has delivered an oral presentation at the world’s leading organization for oncology professionals. Dr. Durm presented an oral abstract about a Phase II lung cancer clinical […]

LUN14-179 accepted as ASCO oral presentation

Hoosier Cancer Research Network’s LUN14-179 study was accepted as an oral presentation to the American Society of Clinical Oncology (ASCO) Annual Meeting, June 1-5, 2018, at the McCormick Place in Chicago.

Award advances retrospective analysis of HCRN LUN14-179

Investigators working on the HCRN LUN14-179 study, which involved the use of concurrent chemoradiation with consolidation pembrolizumab for unresectable stage III non-small cell lung cancer, anticipated that some patients would experience pneumonitis. But they did not know which of their patients might be more susceptible than others. To learn more about the rates of pneumonitis […]

Researchers test combination immunotherapy in mucosal melanoma

Mucosal melanoma is a rare form of cancer, constituting about 1 percent of all melanoma cases. The disease arises from the pigment-producing melanocytes present in the body’s mucosal tissue, and is most commonly found in the head and neck region, anorectal region, and female genital tract. Unlike the far more common cutaneous melanomas, mucosal melanomas […]

Caris Life Sciences selected to perform genomic profiling for UC-GENOME study

The Bladder Cancer Genomics Consortium (BCGC) and Hoosier Cancer Research Network today announced the selection of Caris Life Sciences® to perform genomic profiling for UC-GENOME, a large-scale genomically driven bladder cancer study. The study, also known as HCRN GU15-217, is the first project of the BCGC, a collaborative effort between the Bladder Cancer Advocacy Network […]

Genomic analysis and biorepository research study takes aim at metastatic bladder cancer

Hoosier Cancer Research Network is partnering with the Bladder Cancer Advocacy Network (BCAN) to conduct a large-scale bladder cancer genomic analysis and biorepository research study. Known as UC-GENOME (HCRN GU15-217), the research study is the first project of the Bladder Cancer Genomics Consortium (BCGC), a collaborative effort between BCAN and major medical centers. The BCGC’s […]

HCRN study tests mFOLFIRINOX combined with ramucirumab in advanced pancreatic cancer

Researchers investigating many types of cancers have celebrated significant breakthroughs over the years. Yet, some cancers lag well behind these successes. Pancreatic cancer remains one of the most difficult to treat cancers. In 2016, about 53,000 new pancreatic cancer cases were diagnosed in the United States, and nearly 42,000 people died of their disease. Despite […]

Study tests combination immunotherapy in advanced bile duct cancer

Cholangiocarcinoma, also known as bile duct cancer, is steadily rising in incidence worldwide. Symptoms often go undetected until the disease is far advanced. Surgical resection of tumors is considered the best approach toward attempting a cure, but less than half of patients whose tumors are surgically resected survive past five years, and those whose tumors […]

Study tests nivolumab, ipilimumab in treatment-naive kidney cancer

Hoosier Cancer Research Network (HCRN) announces the opening of a study for patients with advanced renal cell carcinoma who have not received prior treatment for their kidney cancer. The phase II clinical trial, known as HCRN GU16-260, involves front-line therapy with nivolumab and salvage therapy with nivolumab and ipilimumab. The study may help researchers determine […]

HCRN study compares sequence of immunotherapy and anti-angiogenic drugs in metastatic kidney cancer

A new Hoosier Cancer Research Network study may help researchers learn whether the order in which two drugs are given has any effect on progression-free survival — the length of time it takes for cancer to grow or spread. The randomized phase II study, known as HCRN GU15-223, will compare overall progression-free survival for two […]

Three HCRN studies accepted to ASCO 2017

Abstracts from three Hoosier Cancer Research Network studies were accepted to the American Society of Clinical Oncology (ASCO) 2017 Annual Meeting, June 2-6 at the McCormick Place in Chicago. The studies include LUN14-179 (poster session and discussion), GU14-206 (poster session and discussion), and GI14-186 (poster session).

Study tests safety, efficacy of pembrolizumab and Y90 in locally advanced hepatocellular carcinoma

Hepatocellular carcinoma is an aggressive cancer that is often difficult to treat due to the typical accompanying diagnosis of cirrhosis. For patients who qualify for curative treatment, surgery and liver transplant may be considered. However, most patients are not eligible for curative therapy, and instead may be offered liver-directed or systemic therapies that may extend […]

Results from three HCRN studies presented at GU ASCO

Three Hoosier Cancer Research Network studies were featured in poster sessions during the 2017 Gastrointestinal Cancers Symposium, Feb. 16-18 in Orlando.

Study compares chemotherapy with or without nivolumab in advanced non-small cell lung cancer

A new study led by researchers at the Indiana University Melvin and Bren Simon Cancer Center may help answer questions about the role of immunotherapy in combination with chemotherapy in treating lung cancer patients whose disease did not response to immunotherapy. The randomized phase II study, known as HCRN LUN15-233, involves chemotherapy with or without […]

OncoGenex announces positive survival results for GU12-160 study

OncoGenex Pharmaceuticals, Inc. has announced positive survival results from the final analysis of the Phase 2 Borealis-2™ trial of apatorsen in combination with docetaxel treatment that enrolled 200 patients with metastatic bladder cancer whose disease had progressed following first-line platinum-based chemotherapy. The trial, also known as HCRN GU12-160, was conducted by the Hoosier Cancer Research […]

HCRN study tests efficacy of supportive therapy with ginseng for patients receiving regorafenib

A new Hoosier Cancer Research Network study is evaluating whether ginseng can help lessen fatigue in patients treated with regorafenib. The study, known as GI14-191, builds on earlier research that showed daily use of American ginseng significantly decreased the level of fatigue experienced by cancer patients undergoing treatment. GI14-191 focuses on patients receiving regorafenib for […]

HCRN study combines bone-targeting drug with androgen deprivation therapy for metastatic prostate cancer

Hoosier Cancer Research Network (HCRN) announces the launch of a cancer clinical trial for subjects with newly diagnosed metastatic prostate cancer with bone metastases. The study, known as GU13-170, will compare the good and bad effects of adding Radium-223 dichloride, a bone-targeted drug, to androgen deprivation therapy, the usual treatment for this type of cancer. […]

New study evaluates efficacy of immunotherapy drug in treatment of incurable germ cell tumors

Hoosier Cancer Research Network (HCRN) recently launched a cancer clinical trial evaluating the efficacy of the PDL-1 inhibiting drug pembrolizumab in the treatment of patients with incurable platinum refractory germ cell tumors. The study, known as HCRN GU14-206, is now open to accrual at the Indiana University Melvin and Bren Simon Cancer Center. This is […]

Four HCRN studies accepted to ASCO 2016

Abstracts from four Hoosier Cancer Research Network studies were accepted to the American Society of Clinical Oncology (ASCO) 2016 Annual Meeting, June 3-7 at the McCormick Place in Chicago. The studies include GU12-157 (poster session), GU14-188 (poster session), GU14-202 (poster session), and LUN14-179 (publication-only abstract).

HCRN opens clinical trial for subjects with metastatic castrate-resistant prostate cancer

Hoosier Cancer Research Network is pleased to announce the opening of a cancer clinical trial for subjects with metastatic castrate-resistant prostate cancer at select sites throughout the United States. The study, known as GU14-202, is designed to assess the safety and toxicity of an investigational drug called niraparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, given […]

HCRN study compares pembrolizumab to placebo as maintenance therapy in metastatic bladder cancer

A new Hoosier Cancer Research Network study is exploring the effects of pembrolizumab in treating metastatic urothelial cancer. The study, known as GU14-182, will compare maintenance pembrolizumab to a placebo in subjects after first-line chemotherapy for metastatic urothelial cancer (e.g., cancer of the bladder, urethra, ureter, or renal pelvis). The study is currently open to […]

Galsky presents oral abstract on GU10-148

In an oral abstract session at the 2016 Genitourinary Cancers Symposium, Matthew Galsky, MD, reported on the HCRN GU10-148 study, a phase II trial of gemcitabine and cisplatin plus ipilimumab as first-line treatment for patients with metastatic urothelial carcinoma. Dr. Galsky (pictured), of the Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, is […]

Investigators report on QL12-153 study

In a new journal article published online ahead of print in Supportive Care in Cancer, Hoosier Cancer Research Network investigators reported on results of QL12-153, a phase II study of fosaprepitant + 5HT3 receptor agonist + dexamethasone in patients with germ cell tumors undergoing 5-day cisplatin-based chemotherapy. The multi-center study was led by sponsor investigator […]

HCRN study combines immunotherapy and chemotherapy in advanced colorectal cancer

Hoosier Cancer Research Network recently opened a cancer clinical trial for subjects with advanced colorectal cancer. The study, known as GI14-186, involves the study drug called pembrolizumab, given in combination with mFOLFOX6, a standard chemotherapy regimen for advanced colorectal cancer. The study is currently open to accrual at the Indiana University Melvin and Bren Simon […]

HCRN forms new working group for symptom management

Hoosier Cancer Research Network recently launched a Symptom Management Clinical Trial Working Group. The group grew out of a desire to see improvements in quality of life for patients, from diagnosis through survivorship. Formation of the group was sparked by Julie Otte, PhD, RN, OCN from the Indiana University School of Nursing and her commitment […]

OncoGenex announces completion of enrollment for Borealis-2

OncoGenex Pharmaceuticals, Inc., recently announced that Borealis-2™, an investigator-sponsored, randomized Phase 2 trial, has met its target enrollment of 200 patients. Designed to evaluate apatorsen in combination with docetaxel in patients with advanced or metastatic bladder cancer who have disease progression following first-line platinum-based chemotherapy, Borealis-2 is managed by Hoosier Cancer Research Network and is […]

GU07-122 bladder cancer study published in Urologic Oncology

A new journal article on Hoosier Cancer Research Network’s GU07-122 study will appear in the October 2015 issue of Urologic Oncology. The study was designed to determine feasibility and safety of treatment with dasatinib administered orally once daily for 4 weeks duration prior to radical cystectomy for urothelial carcinoma of the bladder.

Genomic profiling study brings personalized medicine to metastatic bladder cancer patients

The Bladder Cancer Advocacy Network (BCAN) and Paradigm today announced a partnership for the launch of a large-scale genomically-driven bladder cancer study. Hoosier Cancer Research Network (HCRN) will act as the coordinating center. This prospective study is the first project of the Bladder Cancer Genomics Consortium (BCGC), a collaborative effort between BCAN and major medical […]

Four abstracts accepted to ASCO 2015

Abstracts from four Hoosier Cancer Research Network studies have been accepted by the American Society of Clinical Oncology (ASCO) for the 2015 Annual Meeting in Chicago on May 29 – June 2. The studies include GU10-148 (poster discussion), BRE09-146 (poster), GI05-102 (poster), and QL12-153 (publication-only abstract).

Reps for Research donations to support lung cancer research

This spring, Hoosier Cancer Research Network Chairman Christopher A. Fausel, PharmD, offered a unique challenge to friends and supporters of HCRN. Combining his interest in strength training and his passion for investigator-initiated research, Fausel invited pledges for every bench-press “rep” he could complete at the Arnold Sports Festival’s 5K Pump and Run event in Columbus, […]

Fisher Award recipient explores immunotherapy targets in circulating tumor cells

Gregory A. Durm, MD, a hematology/oncology fellow at the Indiana University School of Medicine, is helping to break new ground in the fight against cancer by studying circulating tumor cells (CTCs) in lung cancer. CTCs are cells that have broken away from primary tumors and have entered into the bloodstream. CTCs that survive the bloodstream’s […]

HCRN opens PD-1 inhibitor trial for non-small cell lung cancer

Hoosier Cancer Research Network is pleased to announce the opening of a cancer clinical trial for patients with stage III non-small cell lung cancer at select sites throughout the United States. The study, known as LUN14-179, seeks to determine if the use of an investigational drug, Pembrolizumab, following standard chemoradiation treatment, improves the time to […]

Galsky receives Danny Danielson Translational Innovation Award

Hoosier Cancer Research Network, formerly known as Hoosier Oncology Group, recently honored Matthew Galsky, MD, as recipient of the Danny Danielson Translational Innovation Award. The $10,000 award, granted by the Walther Cancer Foundation through the generous support of business and civic leader Donald C. “Danny” Danielson, is given twice each year to investigators working in […]

New breast trial incorporates advanced genomic technology

Indiana University cancer researchers are testing whether therapy incorporating advanced genomic technology will provide better outcomes than current treatments for those with an aggressive form of breast cancer. Researchers at the Indiana University Melvin and Bren Simon Cancer Center, led by Bryan Schneider, M.D., associate professor of medicine, and Milan Radovich, Ph.D., assistant professor of […]

New breast trial incorporates advanced genomic technology

GU02-41 prostate cancer study published in Clinical Genitourinary Cancer

Congratulations to the GU02-41 team!

GU02-41 prostate cancer study published in Clinical Genitourinary Cancer

Congratulations to the GU02-41 team!

LUN05-99 manuscript accepted by the Journal of Thoracic Oncology

Hoosier Oncology is pleased to announce that study LUN05-99 – “Paclitaxel plus Bevacizumab in Patients with Chemosensitive Relapsed Small Cell Lung Cancer (SCLC): A Safety, Feasibility and Efficacy Study” has been accepted by the Journal of Thoracic Oncology. Congratulations to Dr. Jalal and the entire team.

Category: HCRN Research